VilonvsVIP

Vilon (Lys-Glu) is a synthetic dipeptide bioregulator developed as part of the Khavinson peptide bioregulator program, designed to mimic the immune-regulatory effects of thymic peptides in the shortest possible amino acid sequence. As a dipeptide, it is one of the smallest molecules proposed to have specific gene-regulatory activity — which is both its appeal (simplicity, stability, oral bioavailability) and the source of scientific skepticism (whether a two-amino-acid molecule can have specific transcriptional effects).

Vilon is proposed to regulate thymic function and T-cell immunity through the peptide bioregulator mechanism: penetrating cell membranes, entering the nucleus, and interacting with specific DNA sequences in immune-related gene promoters. The reported effects include enhanced T-cell differentiation from thymic precursors, improved balance between CD4+ helper and CD8+ cytotoxic T cell populations, and modulation of cytokine production toward a more balanced Th1/Th2 immune profile.

Preclinical and clinical studies from the Khavinson group have reported that Vilon treatment enhances immune surveillance (the ability of the immune system to detect and eliminate abnormal cells), improves vaccine responsiveness in elderly subjects, and partially reverses age-related immunosenescence markers. In combination with Epithalon (another Khavinson bioregulator targeting telomerase and the pineal gland), Vilon was reported to reduce mortality in a long-term follow-up study of elderly subjects in St. Petersburg. The proposed mechanism for immune enhancement involves restoration of thymic peptide signaling that declines with age-related thymic involution, essentially providing a minimal molecular signal that tells immune progenitor cells to differentiate and mature. As with all Khavinson bioregulators, independent validation through Western clinical trial standards is still needed.

Vasoactive Intestinal Peptide is a 28-amino-acid neuropeptide that belongs to the secretin/glucagon superfamily. It is widely distributed throughout the body — found in neurons of the central and peripheral nervous systems, immune cells, and the gastrointestinal tract — and acts through two G protein-coupled receptors: VPAC1 (expressed broadly) and VPAC2 (more restricted to CNS and immune tissue). Both receptors couple to Gs proteins, activating adenylyl cyclase and raising intracellular cAMP.

VIP's vasodilatory effect is among the most potent in the body. It relaxes vascular, airway, and gastrointestinal smooth muscle by activating cAMP/PKA signaling, which phosphorylates myosin light chain kinase and reduces calcium sensitivity in smooth muscle cells. In the pulmonary vasculature, this produces bronchodilation and reduced pulmonary artery pressure. In cerebral vasculature, VIP is a key regulator of blood flow.

The immunomodulatory effects are particularly relevant for its use in chronic inflammatory response syndrome (CIRS). VIP powerfully suppresses the Th1 (pro-inflammatory) immune response while promoting Th2 and regulatory T cell (Treg) differentiation. It inhibits macrophage production of TNF-α, IL-6, IL-12, and nitric oxide, and suppresses dendritic cell maturation and antigen presentation. This immune-balancing effect makes VIP valuable in conditions characterized by chronic Th1/Th17 immune dysregulation, such as mold illness/CIRS. In the brain, VIP is neuroprotective — it upregulates BDNF and activity-dependent neuroprotective protein (ADNP), supports circadian rhythm regulation in the suprachiasmatic nucleus, and protects neurons from inflammatory and oxidative damage. The extremely short plasma half-life (1-2 minutes) necessitates intranasal delivery for CNS effects, bypassing the blood-brain barrier through olfactory and trigeminal nerve transport.